Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01102244 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis
A Phase 3 study of Blepharitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT01102244: Completed Phase 3 study of Blepharitis, sponsored by Alcon Research.
NCT01102244 is a Phase 3 study of Blepharitis that has completed, run by Alcon Research. The registered enrollment target is 122 participants, above the 40-participant average among 6 other Blepharitis trials with a reported enrollment target (205% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01102244, a Phase 3 study of Blepharitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the clinical efficacy and safety of Tobradex ST compared to AzaSite in the treatment of moderate to severe chronic blepharitis.
Conditions Studied
Interventions
- DRUG Tobradex ST
- DRUG Azasite
Study Locations (1)
Massachusetts
- Ora - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2010-04 |
| Phase | Phase 3 |
What the finished NCT01102244 record still lists
NCT01102244 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, above the 40-participant average among 6 other Blepharitis trials with a reported enrollment target (205% higher).
The record links to 1 condition, with Blepharitis appearing as the primary indexed condition, and to 2 interventions - of which Tobradex ST is the first listed.
NCT01102244 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01102244 about?
NCT01102244 is a clinical study titled "A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis". The purpose of this study is to evaluate the clinical efficacy and safety of Tobradex ST compared to AzaSite in the treatment of moderate to severe chronic blepharitis.
What is the current status of trial NCT01102244?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 122 participants. The study started on 2010-04.
What conditions does trial NCT01102244 study?
This clinical trial studies the following conditions: Blepharitis.
What interventions are being tested in trial NCT01102244?
The interventions under investigation include: Tobradex ST (DRUG), Azasite (DRUG).
Who is sponsoring clinical trial NCT01102244?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01102244 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blepharitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of SUMMIT BRUSH in Treatment of Blepharitis
RECRUITING · NA
-
Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex
ACTIVE NOT RECRUITING · Phase 2
-
Corneal Epithelial Stem Cells and Dry Eye Disease
COMPLETED · NA
-
Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
COMPLETED · Phase 4
-
Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
COMPLETED · Phase 4
-
Treatment of Patients With Blepharitis and Facial Rosacea
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia